First of these on Bluesky! 🚀
Excited to share our cost-effectiveness analysis of the cardiovascular polypill, published in JAMA Cardiology: https://jamanetwork.com/journals/jamacardiology/fullarticle/2828599
Co-authored with @kbibbinsdomingo.bsky.social and many talented but Blueskyless colleagues.
#CardioSky
#EpiSky
#HealthEcon
Excited to share our cost-effectiveness analysis of the cardiovascular polypill, published in JAMA Cardiology: https://jamanetwork.com/journals/jamacardiology/fullarticle/2828599
Co-authored with @kbibbinsdomingo.bsky.social and many talented but Blueskyless colleagues.
#CardioSky
#EpiSky
#HealthEcon
Comments
Lower-income and Black individuals experience disproportionately high rates of cardiovascular disease (CVD), partly explained by:
- high hypertension rates
- clinical inertia
- missed visits
- constrained access to consistent health care
- disparities in treatment adherence
Recruited CVD-free adults aged 40-75 years with elevated blood pressure (SBP) 120-160 mmHg.
The population was majority lower-income (75% with annual income <$15,000 per year) and Black (96%, race self-reported by participants).
After 1 year, the polypill group experienced greater SBP (7 mmHg) and LDL cholesterol (11 mg/dL) reductions than those in the usual care group.
No comparable polypill is currently commercially available in the US.
Used a computer simulation to project long-term costs and health benefits (expressed in quality-adjusted life years, or QALYs) of the polypill.
Analyzed 2 cohorts: a trial-representative cohort and all trial-eligible non-Hispanic Black US adults